Section 05
Business Model
Platform model: multiple revenue streams from quiz to concierge
TL;DR
BioForge makes money at every step of the customer journey. Free quiz brings them in, $29/month app keeps them engaged, $365/year blood work has 75-85% margins, peptide subscriptions at $149-499/month are the core revenue, and premium tiers ($5K-50K/year) drive the highest profit per customer. We don't build the medical or pharmacy infrastructure — we partner with existing platforms (like Medvi did) and own the brand, the app, and the customer relationship. Start with $22K, profitable by month 8-10.
Avg Revenue/Customer
$200/mo
Gross Margin (Y5)
72%
LTV:CAC
5.1x
Payback Period
1.75 mo
BioForge operates a platform model with multiple revenue streams across a value ladder from $0 to $50K/year. The "thin layer" approach (proven by Medvi) means we own the brand, customer relationship, and AI-driven operations, while all regulated functions — medical consultations, prescriptions, compounding, and fulfillment — are handled by licensed third-party partners. Revenue comes from app subscriptions ($29/mo), blood work panels ($365/yr, 75-85% margin), peptide subscriptions ($149-499/mo), consultation fees, and premium plans ($5K-50K/yr). Self-funded with $22K. proven by Medvi: a technology and marketing layer sitting atop outsourced telehealth and pharmaceutical infrastructure. Self-funded with $22K (like Medvi's $20K start), all regulated functions — medical consultations, prescriptions, compounding, and fulfillment — are handled by licensed third-party partners. BioForge owns the brand, the customer relationship, and the AI-driven operational stack. The men-only fitness + longevity positioning creates a sharp brand identity with higher LTV than generic telehealth platforms.
Three-Entity Structure
BioForge (Dubai Free Zone LLC)
Technology & Marketing Layer
- • Brand identity and website
- • Customer acquisition (paid media, SEO)
- • Checkout and payment processing
- • Customer service (AI chatbot + human escalation)
- • Data analytics and AI operations
- • Product strategy and pricing
BioForge explicitly does not provide healthcare services and is not licensed to practice medicine.
Telehealth Partner (e.g., CareValidate, OpenLoop, Wheel)
Clinical Infrastructure
- • Network of licensed US physicians (MD, DO, NP, PA)
- • Patient intake and medical review
- • Independent prescribing decisions
- • HIPAA-compliant data handling
- • State-by-state licensing compliance
Fee: estimated 40-50% of transaction value based on Medvi model.
Compounding Pharmacy Partners (503A/503B)
Pharmaceutical Fulfillment
- • Licensed compounding of prescription peptides
- • Quality assurance and testing
- • Cold-chain packaging and shipping
- • FDA-registered facilities (503B)
- • State-licensed pharmacies (503A)
Cost: estimated 15-25% of transaction value for COGS.
Unit Economics
Average Revenue Per Customer
$170/month ($2,040/year) — men on peptide stacks, growing to $220/mo by Year 5
Cogs
$43/month (pharmacy + shipping)
Platform Fee
$68/month (telehealth partner)
Gross Profit
$59/month per customer
Gross Margin
45% (initially) → 72% (at scale with direct pharmacy relationships)
Cac
$350 target (vs. Medvi's $500-700) — lower due to organic fitness community reach
Ltv
$1,100 initially → $2,300 by Year 5 (men who train have high adherence)
Ltv Cac Ratio
3.1x initially → 8.5x by Year 5
Payback Period
2.1 months
Monthly Churn
12% Year 1, declining to 5% by Year 5 (protocol-driven retention)
Revenue Streams
Monthly peptide memberships ($149-499/mo) and Performance Plans — core revenue driver
$365/year panels via Quest/LabCorp partnership (cost $50-100, margin 75-85%). The gateway product.
Longevity Protocol ($5-10K/yr) and Elite Concierge ($25-50K/yr) — fewer customers, highest revenue per person
BioForge AI app at $29/month — high volume, low delivery cost, 85-90% margin
Telehealth consultation fees, supplement recommendations, branded merchandise
Margin Evolution (5-Year)
2027: Year 1: Lean bootstrap, break-even by month 8-10, small net profit
2028: Year 2: Volume discounts on pharmacy, improved CAC efficiency
2029: Year 3: Direct pharmacy relationships, AI reduces support costs
2030: Year 4: Negotiated platform rates, multi-market revenue
2031: Year 5: Mature operations, potential vertical integration
Scaling Strategy
Organic bootstrap model: self-funded with $22K, reinvest 100% of profits into growth. No external capital unless strategically justified at $5-10M+ revenue. The Medvi insight holds — telehealth-as-a-service platforms scale automatically. BioForge's lean scaling path: Phase 1 (Month 1-10): US market only, 3-5 peptides, founder does everything with AI. Target break-even by month 8-10. Phase 2 (Year 1-2): Scale to $600K-3M revenue. First hire only after revenue justifies it. Expand to 8-10 peptides. Phase 3 (Year 2-3): $3-10M revenue. Add UAE market via DHCC/JAFZA. Direct pharmacy relationships for better margins. Phase 4 (Year 4-5): $10-40M revenue. Optional: raise $2-3M for own 503B pharmacy license (drops COGS from 25% to 10%). Or stay lean and profitable forever like Medvi.